Drugs News and Research

RSS

Form of epigenetics may play role in pulmonary arterial hypertension: Researchers

A rare but fatal disease of blood vessels in the lung may be caused in part by aberrant silencing of genes rather than genetic mutation, new research reports. Pulmonary arterial hypertension, a syndrome characterized by gradual blockage of blood vessels in the lungs, has been linked to genetic causes in a small percentage of patients. But University of Chicago researchers have now found that a form of epigenetics - the modification of gene expression - causes the disease in an animal model and could contribute to the disease in humans.

8 Jun 2010

Can-Fite BioPharma opens CF101 IND for psoriasis with US FDA

Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened Investigational New Drug application (IND) with the United States Food and Drug Administration (US FDA). The IND is for Can-Fite's lead compound, CF101, for the treatment of patients with psoriasis. This is the third US IND for CF101, and the fourth for Can-Fite.

8 Jun 2010

Targeted therapy that benefits patients with metastatic colon cancer fails to help patients with stage III cancer

To the surprise of researchers at Mayo Clinic who led a national clinical trial, a targeted therapy that provides benefit to patients with metastatic colon cancer has failed to help patients with less advanced, stage III cancer. In fact, patients who used the agent, cetuximab, with chemotherapy had outcomes slightly inferior to patients treated with chemotherapy alone.

7 Jun 2010

B2Discovery rallies business leaders in support of excellence in cancer research

The Institute for Research in Immunology and Cancer (IRIC) of the Universit- de Montr-al launches B2Discovery, a new research funding model that brings together the private sector and the biomedical research community to help accelerate the discovery of new anti-cancer therapeutics. Inspired by B2ten, which contributed to the success of several Canadian athletes at the Vancouver Winter Olympics, B2Discovery's mission is to partner entrepreneurs with IRIC's cancer investigators to finance novel and promising research projects not currently funded by public granting agencies.

7 Jun 2010

Angiochem presents positive Phase 1/2 clinical data of ANG1005 for brain cancer at ASCO 2010

Angiochem, Inc., a clinical-stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB) through LRP-1 targeting, announced today that complete phase 1/2 clinical data in two clinical studies of its lead oncology program, ANG1005, for the treatment of brain cancers, including glioblastoma (GBM) and brain metastases, were presented at the 2010 American Society for Clinical Oncology (ASCO) Annual Meeting, June 4-8, in Chicago, IL.

7 Jun 2010

Alnylam presents interim data from ALN-VSP02 Phase I trial for liver cancer at ASCO 2010

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today preliminary clinical data from its ongoing Phase I trial with ALN-VSP, a systemically delivered RNAi therapeutic for the treatment of advanced solid tumors with liver involvement.

7 Jun 2010

PTC receives $5.4M SDD Award to support development of drugs that target Bmi-1

PTC Therapeutics, Inc. today announced the receipt of a $5.4 million Seeding Drug Discovery Award from The Wellcome Trust to support the development of drugs that target Bmi-1, a protein that has been linked to drug resistant cancers.

7 Jun 2010

Aeterna Zentaris presents positive data from AEZS-108 Phase 2 study in ovarian cancer at ASCO 2010

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that it presented positive efficacy and safety data for its doxorubicin targeted conjugate compound, AEZS-108, in ovarian cancer.

7 Jun 2010

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

Novartis Pharmaceuticals Corporation announced today that results from a Phase II study show Afinitor® (everolimus) tablets is the first medication in a clinical trial to decrease the size of subependymal giant cell astrocytomas (SEGAs), benign brain tumors associated with tuberous sclerosis (TS). In this study of 28 patients presented today at the 46th American Society of Clinical Oncology (ASCO) annual meeting in Chicago, 75% of patients experienced a reduction of 30% or greater in the size of their brain tumors from baseline to six months (p<0.001).

7 Jun 2010

O2h signs agreement to provide discovery services to Karyopharm Therapeutics

O2h (Ahmedabad, India) is pleased to announce the signing of an agreement with Karyopharm Therapeutics, Inc. (Newton, Massachusetts, USA) under which O2h will provide Karyopharm discovery services to advance Karyopharm's lead small molecule program toward the nomination of a development candidate.

7 Jun 2010

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

VBL Therapeutics, a clinical-stage biotechnology company committed to the development of novel treatments for immune-inflammatory diseases and cancer, today announced preclinical data demonstrating that VB-201 regulates inflammatory pathways, suggesting that it may effectively control inflammatory responses associated with autoimmune diseases and atherosclerosis.

7 Jun 2010

Bisphosphonates may cause poorer survival rate in women with early stage breast cancer: Study

Scientists from the Barbara Ann Karmanos Cancer Institute in Detroit presented preliminary data that shows nitrogen-containing bisphosphonates, therapeutic agents used to promote bone health and inhibit resorption, may cause a slightly poorer survival rate in post-menopausal women with early stage breast cancer who take them for their anti-osteoporosis properties.

7 Jun 2010

Exelixis reports updated interim data from trials of XL765 small molecule inhibitor of PI3K and mTOR

Exelixis, Inc. today reported updated interim data from three ongoing trials of XL765 (SAR245409), an orally available small molecule inhibitor of phosphoinositide-3-kinase (PI3K) and mTOR. Activation of the PI3K pathway is a frequent event in human tumors, promoting cell proliferation, survival, and resistance to chemotherapy and radiotherapy.

7 Jun 2010

Study identifies potential link between Gilbert's Syndrome, childhood acute lymphoblastic leukemia

Scientists from the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine, both in Detroit, and the Children's Hospital of Michigan/Detroit Medical Center, presented preliminary data that identified a potential link between Gilbert's Syndrome and the development of a specific subtype of childhood acute lymphoblastic leukemia (ALL). The findings were announced today at the 2010 American Society of Clinical Oncology Annual Meeting.

7 Jun 2010

Sexsomnia more common in men than women

Sexsomnia was reported by almost eight percent of patients at a sleep disorders center and was more common in men than women, according to a research abstract that will be presented Monday, June 7, 2010, in San Antonio, Texas, at SLEEP 2010, the 24th annual meeting of the Associated Professional Sleep Societies LLC.

7 Jun 2010

Research focuses on art, pharmaceutical drugs and the environment

Providing solutions to any current problem is the mission of analytical chemistry, according to Ms Rosa Alonso, director of the Farmartem Research Group at the University of the Basque Country. The group's name says it all with respect to the wide range of these problems - Farmartem: the abbreviation in Spanish of pharmaceuticals, art and the environment (f-rmacos, arte, medio ambiente).

5 Jun 2010

Scientific, ethical issues involved in studies of drug safety after FDA approval to be evaluated

The director and a core faculty member of the Johns Hopkins Berman Institute of Bioethics have been appointed co-chairs of an Institute of Medicine committee that will evaluate the scientific and ethical issues involved in studies of drug safety after FDA approval.

5 Jun 2010

Burden of substance abuse casts tragic shadow on the lives of many young people: Report

On an average day, 508,000 adolescents aged 12-17 in the United States drink alcohol; 641,000 use illicit drugs; and more than 1 million smoke cigarettes, according to a national survey sponsored by the Substance Abuse and Mental Health Services Administration.

5 Jun 2010

USC to present promising new findings in cancer research at 2010 ASCO

Faculty at the University of Southern California (USC) and USC Norris Comprehensive Cancer Center will present promising new findings in a number of cancer research areas at the 2010 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from June 4-8.

5 Jun 2010

Celgene reports initial data from investigator-initiated study of REVLIMID

Celgene International Sàrl today announced that initial data from an investigator-initiated study of REVLIMID (lenalidomide) plus Rituxan (rituximab) in patients with newly diagnosed indolent B-cell non-Hodgkin's lymphoma (NHL) were presented at the annual meeting of the American Society of Clinical Oncology.

5 Jun 2010

Drugs News and Research

Form of epigenetics may play role in pulmonary arterial hypertension: Researchers

Can-Fite BioPharma opens CF101 IND for psoriasis with US FDA

Targeted therapy that benefits patients with metastatic colon cancer fails to help patients with stage III cancer

B2Discovery rallies business leaders in support of excellence in cancer research

Angiochem presents positive Phase 1/2 clinical data of ANG1005 for brain cancer at ASCO 2010

Alnylam presents interim data from ALN-VSP02 Phase I trial for liver cancer at ASCO 2010

PTC receives $5.4M SDD Award to support development of drugs that target Bmi-1

Aeterna Zentaris presents positive data from AEZS-108 Phase 2 study in ovarian cancer at ASCO 2010

Novartis' Afinitor decreases size of SEGAs associated with tuberous sclerosis

O2h signs agreement to provide discovery services to Karyopharm Therapeutics

Data shows VB-201 controls inflammatory responses associated with autoimmune diseases, atherosclerosis

Bisphosphonates may cause poorer survival rate in women with early stage breast cancer: Study

Exelixis reports updated interim data from trials of XL765 small molecule inhibitor of PI3K and mTOR

Study identifies potential link between Gilbert's Syndrome, childhood acute lymphoblastic leukemia

Sexsomnia more common in men than women

Research focuses on art, pharmaceutical drugs and the environment

Scientific, ethical issues involved in studies of drug safety after FDA approval to be evaluated

Burden of substance abuse casts tragic shadow on the lives of many young people: Report

USC to present promising new findings in cancer research at 2010 ASCO

Celgene reports initial data from investigator-initiated study of REVLIMID

Drug Discovery - Second Edition eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News